Dabigatran
An anticoagulant that directly inhibits thrombin, a key protein in the blood clotting process. It is used to prevent blood clots and strokes in certain patients.
Molekularmasse
471,5100 g/mol
LogP
1,70
TPSA
150,00 Ų
Lipinski-Regel der Fünf
Bestanden
Therapeutische Bereiche
Arzneimittelklassen
Wirkmechanismus
Direct thrombin (Factor IIa) inhibitor.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Direct thrombin (Factor IIa) inhibitor.
2D-Struktur
Cite this structure
Embed this structure
SMILES
CN1C2=C(C=C(C=C2)C(=O)N(CCC(=O)O)C3=CC=CC=N3)N=C1CNC4=CC=C(C=C4)C(=N)N
InChI
InChI=1S/C25H25N7O3/c1-31-20-10-7-17(25(35)32(13-11-23(33)34)21-4-2-3-12-28-21)14-19(20)30-22(31)15-29-18-8-5-16(6-9-18)24(26)27/h2-10,12,14,29H,11,13,15H2,1H3,(H3,26,27)(H,33,34)
Molecular Formula
C25H25N7O3
HBD / HBA
4 / 7
Rotierbare Bindungen
9
Schwere Atome
35
Ibuprofen with dabigatran increases GI bleeding risk through additive effects; dabigatran itself carries a higher inherent GI bleeding risk than other DOACs.
Diltiazem increases dabigatran plasma levels through P-glycoprotein inhibition, potentially raising bleeding risk without a change in INR (dabigatran has no INR to monitor).
Cyclosporine dramatically increases dabigatran exposure through P-gp inhibition, raising the risk of serious or life-threatening bleeding.
Low-dose aspirin combined with dabigatran increases bleeding risk; clinical evidence suggests a 2-fold increase in major bleeding events.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
An anticoagulant that directly inhibits thrombin, a key protein in the blood clotting process. It is used to prevent blood clots and strokes in certain patients.
Direct thrombin (Factor IIa) inhibitor.
Key pharmacokinetic parameters for Dabigatran: Half-life: 12-17 hours.
Yes, Dabigatran is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
Related Drugs
References & Data Sources
- PubChem — National Center for Biotechnology Information (NCBI). CID 216210. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="dabigatran"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/dabigatran/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/dabigatran/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/dabigatran/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="dabigatran"></drugfyi-drug>